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Introduction: Young patients receiving chemotherapy occasionally face infertility and premature ovarian failure
(POF). Numerous investigations reported that adipose-derived stem cells (ADSCs) transplantation could ameliorate
the structure and function of injured tissues. The aim of this study was to explore the therapeutic efficacy of ADSC
transplantation for chemotherapy-induced ovarian damage.
Methods: Female mice were injected intraperitoneally with 50 mg/kg cyclophosphamide (CTX). After 15
consecutive days of injection, ADSCs were transplanted either directly into bilateral ovaries or via intravenous
injection, and the ovaries were excised after either 1 week or 1 month of treatment. The follicles were counted and
categorized, and ovarian histologic sections were stained for TUNEL. Ovarian function was evaluated by monitoring
ovulation. ADSC tracking, microarray analyses, and real-time polymerase chain reaction (PCR) were used to assess
the inner mechanism of injury and repair.
Results: The ovarian function of mice exposed to CTX injection improved after ADSC transplantation. The
population of follicles at different stages and ovulation significantly increased after the treatment.
Immunofluorescence revealed reduced TUNEL staining. The tracking of ADSCs revealed that these cells did not
directly differentiate into the follicle component. Microarray analyses indicated that changes in different groups of
genes might affect follicle formation or ovulation.
Conclusions: ADSC transplantation improved ovarian function. Our results suggest a potential mechanism for
ADSC therapy.
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Chemicals that are used to treat cancer are unquestion-
ably beneficial as therapeutic agents. However, their side
effect on the quality of life of female cancer survivors
and their offspring cannot be ignored. Females are born
with a finite number of undeveloped, primordial follicles.
Chemicals that destroy primordial oocytes contained in
the ovary can lead to premature ovarian failure (POF) or
menopause [1]. POF is defined as secondary infertility
with persistently elevated gonadotropin levels before the
age of 40, with an estimated 1% incidence [2]. However,
no clear definition exists for chemotherapy-induced
ovarian failure, which is characterized by irreversible* Correspondence: yqyao@126.com
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reproduction in any medium, provided the oramenorrhea lasting more than 1 year after chemotherapy
and follicle-stimulating hormone (FSH) levels more than
30 MIU/ml in the presence of a negative pregnancy test
[3]. Apart from its direct effect on follicles and oocytes,
chemotherapy has consequences, such as hot flashes,
osteoporosis, cardiovascular and neurologic systems dis-
ease, sexual dysfunction, and the risk of infertility [4].
Cyclophosphamide (CTX), an alkylating agent, has irre-
versible cytotoxicity toward ovaries; in particular, it directly
destroys oocytes and arouses follicular depletion [5,6].
Hormonal replacement therapy (HRT) has been used
to treat common menopausal problems, but it increases
the risk of cancer or recurrence in cancer survivors, for-
cing physicians to use alternative treatments. In recent
years, interest has rapidly grown in the therapeutic po-
tential of stem cells. Lee [7] concluded that bone mar-
row stem cells transplantation (BMT) rescued long-term. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recipients are misidentified immune cells. Fu [8] demon-
strated that BMT improves ovarian function in rats with
chemotherapy-induced ovarian damage. However, bone
marrow stem cells used in these previous studies were
limited and caused trauma to the patient. The application
of embryonic stem cells has ethical issues. ADSCs are a
new type of MSC that is typically abundant in individuals,
and their protective role in POF remains obscure.
Adipose-derived stem cells (ADSCs) are a type of
multipotent adult stem cell isolated from adipose tissue.
Cultured ADSCs can differentiate into multiple cell
types, including osteoblasts, cartilage cells, adipocytes,
myocytes, vascular endothelial cells, and neurons [9,10].
The biologic characteristics of ADSCs resemble those of
adult stem cells from marrow [11]. Adipose tissue repre-
sents an abundant, poorly immunogenic, stably prolifer-
ative, low-injury and practical tissue source that holds
great promise for autologous cell repair and regener-
ation. As a result, adipose tissue has become popular
among researchers [12]. As the clinical applicability of
ADSCs has been demonstrated in several clinical trials,
including the treatment of ischemic myocardial dysfunc-
tion, kidney injury, carcinoma, and neuron system dis-
eases, adipose tissue might provide an alternative source
of stem cells for POF. In this study, POF was induced in
mice by CTX treatment, and autologous ADSCs were
directly injected into the ovaries or intravenously.
Materials and methods
Experimental animals
Eight-week-old female C57/BL6 mice and 8-week-old
C57/BL6 female green fluorescent protein (GFP) trans-
genic mice were used in all of the experiments. The mice
were purchased from Vital River Laboratories (Beijing,
China). All of the animal procedures were conducted in
accordance with the Animal Research: Reporting In Vivo
Experiments (ARRIVE) guidelines for reporting animal
studies. Ethical approval was obtained from the Ethics
Committee of Military Medical Sciences (Beijing, China)
for this study. The mice were fed a standard pellet diet
and allowed free access to water. Vaginal smears were
obtained daily. Only mice showing at least two consecu-
tive normal 4– to 5-day vaginal estrus cycles were in-
cluded in the experiments.
Acquisition, identification, and labeling of ADSCs
ADSC isolation was performed according to the protocol
previously reported [13]. In brief, subcutaneous adipose
tissue was acquired from the inguinal region of mice.
Next, adipose tissues were washed extensively with ster-
ile phosphate-buffered saline (PBS) to remove contamin-
ating debris and red blood cells. Next, the tissue was
minced with scissors and digested with 0.1% type Icollagenase (Sigma, US) in serum-free medium. The di-
gestion was performed at 37°C for 30 to 60 minutes with
gentle agitation. Then the enzymes were inactivated with
an equal volume of α-MEM (Gibco, US) supplemented
with 10% fetal bovine serum (FBS, Gibco), and the sam-
ples were filtered through a 200-μm mesh filter to remove
debris. Then they were centrifuged at 600 g for 5 minutes
to obtain cellular pellets. The cellular pellets were cultured
in α-MEM/10% FBS, 50 U/ml penicillin, and 50 μg/ml
streptomycin in a humidified incubator at 37°C with 5%
carbon dioxide. Third-passage ADSCs were used for all of
the transplantation experiments.
Surface-marker expression was analyzed with flow cytom-
etry by using the following antibodies: fluorescein isothio-
cyanate (FITC)-conjugated mouse monoclonal antibodies
against CD29, CD44, CD90, CD31, and CD45, and phyco-
erythrin (PE)-conjugated mouse monoclonal antibodies
against CD34 (Biolegend, US). For flow cytometric ana-
lysis, adherent cells were detached by treatment with
0.25% trypsin-EDTA, neutralized with FBS-containing
culture medium, and disaggregated into single cells by
pipetting. The cells were incubated with mAbs for 30 mi-
nutes at 4°C, washed twice with PBS, resuspended in 0.5
ml PBS, and immediately analyzed by using an FACS
Calibur flow cytometer (Becton Dickinson, US). A mini-
mum of 2 × 105 cells wase used for each sample, and cell
Quest software was used for data analysis.
To confirm the multipotency of ADSCs, osteogenic
and adipogenic differentiation were verified with Ali-
zarin Red staining and Oil Red O staining, respectively
[12]. In brief, to achieve osteogenic differentiation, cells
were seeded onto the six-well plate at a density of
2 × 103 cells/cm2. After 24 hours, the medium was re-
placed by osteogenic differentiation medium, and the
cells were induced for 3 weeks. Then cells could be fixed
and stained with Alizarin red; to achieve osteogenic differ-
entiation, cells were seeded at a density of 1 × 104/cm2.
After reaching confluence, cells were incubated in
adipogenic differentiation medium for 2 weeks. Then cells
were fixed and stained with Oil Red O. The differentiation
medium was changed every 3 days.
Animal model establishment
To establish the POF model of chemotherapy-induced
ovarian damage, adult female C57/BL6 mice were admin-
istered CTX (50 mg/kg) for 15 consecutive days via intra-
peritoneal injection.
ADSC transplantation
After establishing the POF model, we randomly divided
the mice into four equal groups. The WT group consisted
of normal control mice that received no treatment. In the
POF group, the mice were administered CTX. In the
intravenous group, POF mice were injected intravenously
Table 1 Primers used in this study




Cxcr4 NM_009911.3 F TCAAGCAAGGATGTGACTTCG
R GGCATAGAGGATGGGGTTCA 101
Onecut2 NM_194268.2 F AGAGGGTTCTATGCCGGTCT
R CTTTGCGTTTGCATGCTGCC 171
Bpil3 NM_199303.2 F AGCACCCGAAGTCACTCTTC
R AGTTAACTCCGCCTCGTGGA 161
Angpt1 NM_009640.3 F TGCTAACAGGAGGTTGGTGG
R GGCCCTTTGAAGTAGTGCCA 121
Zcchc11 NM_175472.3 F CAGCCCAAACCCTTCTATGC
R CGGATACCCTTGAGACAGCAG 143
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0.1 M PBS (pH 7.4). The injection was repeated again the
following day. In the in situ group, 1 × 105 ADSCs in 20 μl
PBS were injected directly into the bilateral ovaries of
POF mice with a microinjector.
Ovarian follicle counts and morphologic analysis
ADSCs were administered either intravenously or in situ.
The ovaries were collected 1 week and 1 month after treat-
ment, and the follicles were detected and classified. Five
representative sections from each ovary were selected.
The ovaries were removed and fixed in 4% paraformalde-
hyde for at least 24 hours. After fixation, the ovaries were
dehydrated, paraffin-embedded, serially sectioned at 5 μm,
and mounted on glass microscope slides. Routine
hematoxylin and eosin (H&E) staining was performed for
histologic examination with light microscopy. Primordial,
primary, secondary, and antral follicles were counted on
every fifth section. Only follicles containing an oocyte were
counted to avoid counting any follicle twice. Follicles were
classified as follows: primordial follicle, oocyte surrounded
by a single layer of squamous granulosa cells; primary fol-
licle, intact enlarged oocyte with a visible nucleus and one
layer of cuboidal granulosa cells; secondary follicle, two or
three layers of cuboidal granulosa cells without antral space;
early antral follicles, emerging antral spaces; and preovula-
tory follicles, which are largest of the follicular types and
possess a defined cumulus granulosa cell layer [14].
Mouse superovulation
Four groups of female C57/BL6 mice were superovulated
1 week or 1 month after transplantation via an intraperito-
neal injection of 5 IU pregnant mare serum gonadotropin
(PMSG), followed by intraperitoneal injection of 5 IU hu-
man chorionic gonadotropin (HCG) 48 hours later. The
oocytes were collected from the ampulla portion of the
oviduct 14 to 16 hours after HCG injection.
TUNEL assay
An in situ Cell Death Detection Kit, POD (Roche,
Germany), was used to detect apoptosis in the mouse
ovaries, according to manufacturer’s instruction. Next,
the nucleus was dyed with Hoechst 33324, and the sec-
tions were observed with fluorescence microscopy
(Olympus, Japan). Apoptotic granulosa cells (GCs) in
the ovary were stained green, and five random fields
from each sample were counted (five samples/group).
Cell-tracking studies
For cell-tracking studies, C57/BL6 female GFP transgenic
mice were used as donors, and C57/BL6 female mice
served as receptors. GFP-positive ADSCs were acquired as
described previously [15]. The transplanted mice were
killed 1 week and 1 month after transplantation of ADSCs.The ovaries were collected and made into frozen sections.
The oocytes were collected from the ampulla portion of the
oviduct 14 to 16 hours after HCG injection. The sections
and oocytes were observed with fluorescence microscopy
(Olympus).
Microarray and real-time PCR analysis
RNA was isolated from mouse ovaries by using Trizol
(Invitrogen) with standard methods. Labeling and hybrid-
ization were performed at the CapitalBio Company,
according to protocols described in the 32 K mouse
genome arrays user manual. The data were analyzed by
using LuxScan 3.0 Image analysis software (CapitalBio
Company, China).
Real-time quantitative PCR reactions were set up in trip-
licate by using the SYBR Green Real-time PCR Master Mix
(Applied Biosystems, US) and run on a Bio-Rad CFX96
(US). The PCR primers were designed according to cDNA
sequences in the NCBI database (Table 1). All of the gene-
expression levels were normalized to the internal standard
gene, Gapdh. For expression analysis, data from three repli-
cates were analyzed by using the 2−ΔΔCt method.
Statistical analyses
The statistical analyses were performed by using SPSS 14.
The mean ± SEM of the data were calculated. Student
t tests were used to determine the significance between
two groups. One-way analysis of variance (ANOVA)
with least significant difference (LSD) tests was used to
determine significant differences between four groups. A
P value < 0.05 was considered to be statistically significant.
Results and discussion
Cultivation and characterization of mouse ADSCs
Isolated cells were cultured in tissue-culture dishes.
After 4 days in culture, the cells appeared to be spindle
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After approximately three passages (Figure 1A), FACS
analysis was used to identify the expression of surface
markers. Most of the adherent cells expressed CD29,
CD44, and CD90. Those markers were expressed in
more than 95% of the population. In contrast, the major-
ity of adherent cells were negative for CD31, CD34, and
CD45 (Figure 1B). These ADSC were multipotent, as de-
termined by their ability to differentiate into osteoblasts
and adipocytes (Figure 1C).
Zuk [9] first reported the isolation of ADSCs from adi-
pose tissue in 2001. As a novel source of MSCs, adipose
tissue is typically abundant, poorly immunogenic, fast
growing, minimally invasive, safe for autologous trans-
plantation, avoids ethical problems, and is superior to
other sources [13].Follicle number of the ADSC transplantation group
increased after therapy
Hematoxylin and eosin staining indicated that the POF
group (Figure 2A(b)) had fewer follicles than the WT
(Figure 2A(a)) and ADSC transplantation (Figure 2A(c, d))
groups. One week after transplantation, the numbers of
follicles in the ovaries of female mice that received ADSCs
via intravenous or in situ routes were increased. The ovar-
ies of mice that received ADSC transplantation after
chemotherapy possessed several hundred follicles at all
stages of development. In contrast, the POF mice did not
recover to the normal level within 1 month. Thus, both
intravenous and in situ therapy significantly reduced
ovary injury. After 1 week, the number of primary (357 ±Figure 1 The isolation and identification of ADSCs. (A) The ADSCs exh
cells were positive for CD29, CD44, and CD90 and negative for CD31, CD34
Scale bars: 100 μm.15.38), early antral follicles (476 ± 77.73) and antral folli-
cles (377 ± 39.45) in the in situ group were significantly
greater than those of the POF group (P < 0.05). Moreover,
the amounts of other types of follicles in the intravenous
and in situ groups were greater than those of the POF
group, but these differences did not reach statistical sig-
nificance. After 1 month, the number of primordial
(278 ± 24.9), secondary (470 ± 57.45), early antral (320 ±
14.14), and preovulatory follicles (321 ± 42.49) in the in
situ group, and the number of primary (252 ± 33.47), sec-
ondary (456 ± 62.29), early antral (352 ± 22.8), and preovu-
latory follicles (316 ± 38.47) in the intravenous group
were significantly increased compared with the POF
group (P < 0.05) (Figure 2C, D).
Several routes have been reported for the delivery of
stem cells for ovarian repair, including intravenous [7]
and in situ injection [8]. Both of these methods were
used in this study and to compare their therapeutic ef-
fect. The results indicated that both methods improved
ovary function and increased the numbers of follicles.Ovulation of the ADSC administration group increased
after therapy
Four female mice per group were injected with PMSG
and hCG to induce superovulation. A subset of the oo-
cytes in the POF group displayed an abnormal shape,
with fragmentation and apoptosis in the cytoplasm. The
ovulation number of the POF group (12.6 ± 5.6, n = 9)
(Figure 3B) significantly decreased compared with the
control group. After 4 weeks, ovulation remained low
(13.2 ± 5, n = 6). However, in the intravenous (32.56 ±ibited typical fibroblastic morphology. (B) FCM analysis of ADSCs. The
, and CD45. (C) ADSCs differentiate into osteoblasts and adipocytes.
Figure 2 The follicle number increased after transplantation. (A) Hematoxylin and eosin staining. (a) Most of the follicles of WT and ADSCs
were secondary and antral follicles. The population of follicles decreased significantly after injection with CTX (b) and recovered after the ADSCs
both intravenous and in situ therapy (c, d). The POF model mouse had fewer follicles and most of them were primary and secondary follicles or
had no function. (B) The number of follicles after one week. (C) The number of follicles after 1 month. Scale bars: 200 μm. (*P < 0.05 in situ versus
POF group; #P < 0.05 intravenous versus POF group).
Figure 3 The ovulation increased after therapy. (A) The oocytes of the WT group. (B) The oocytes in the POF model exhibited abnormal
morphology and number. (C) The oocytes of the intravenous group. (D) The oocytes of the in situ group. (E, F) The population of oocytes
increased after 1 week and 1 month of ADSC therapy. (*P < 0.05 intravenous versus the POF group, #P < 0.05 in situ versus the POF group).
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Figure 4 The apoptosis of ovaries reduced after ADSC therapy. The ovaries of WT group (A, E), POF group (B, F), the intravenous group
(C, G), and the in situ group (D, H). The green stain indicates TUNEL-positive GCs. The blue stain indicates the nucleus. Data from one week
demonstrate that apoptosis was attenuated by the transplantation of ADSCs. (I) The number of apoptotic GCs decreased after 1 week of ADSC
therapy. Scale bars: 100 μm (*P < 0.05 intravenous versus POF group, #P < 0.05 in situ versus POF group).
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groups (33.67 ± 8.63, n = 9, P < 0.05 versus POF group),
ovulation increased 1 week after treatment (Figure 3).
Apoptosis in the ovaries decreased after ADSC
transplantation
One week after ADSC transplantation, the number of
cells that stained positive for TUNEL in ovary sections
was quantified. The number of apoptotic GCs in the POF
group (150.8 ± 48.4/mm2) was significantly higher than
that of the other groups (P < 0.05). The number of
TUNEL-positive cells in the intravenous (42.8 ± 13.7/mm2)
and in situ (50.4 ± 13.1/mm2) groups was lower than that
of the POF group (Figure 4). The apoptosis in the therapy
group was reduced and closer to that of the control group
(33.2 ± 10.3/mm2). Both of the therapeutic methods re-
duced host apoptosis.Figure 5 ADSCs tracking in vivo. (A) GFP (+)-ADSCs under a light micros
week and 1 month after transplantation, ADSCs can be traced in the intrav
ADSCs can be traced in the in situ group. (G) ADSCs can not be traced in WPrevious studies conclusively demonstrated that alkyl-
ating agents induce apoptosis in GCs and oocytes, and
consequently, the loss of follicles [8,16]. This study indi-
cates that both in situ and intravenous transplantation of
ADSC rescues the apoptosis of GCs in ovary sections.
ADSCs tracking in vivo
Cell tracking is generally used to monitor stem cell hom-
ing and engraftment. One week and 1 month after trans-
plantation, the injected GFP (+)-ADSCs were traced to
the ovary, and GFP-positive cells were located in the
interstitium but not in follicles (Figure 5). We also exam-
ined oocytes and cumulus cells from recipient ovaries, and
we did not observe green fluorescence (Figure 6).
Careful observation is needed to determine whether
stem cell transplantation constitutes regenerative cell
therapy or cell-based cytokine therapy and to determinecope. (B) GFP (+)-ADSCs under a fluorescence microscope. (C, E) One
enous group. (D, F) One week and 1 month after transplantation,
T group. Scale bars: 100 μm.
Figure 6 Transplanted ADSCs were not formed into oocytes. (A) Oocytes and cumulus cells from donor ovaries showed green fluorescence.
(B, C) Oocytes and cumulus cells from recipient ovaries did not show green fluorescence. Scale bars: 100 μm.
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Considering their strength and stability, GFP-positive
ADSCs were used in this study. We found that ADSCs
undergo a massive cell loss after intravenous injection,
resulting in low signal intensity, which was consistent
with previous reports. At 4 weeks, only a small portion
of transplanted ADSCs could be detected in the intra-
venous group with immunofluorescence. We also ob-
served that the interstitium in the therapy group
exhibited fluorescent stem cells that had infused into the
donor ovary, but these cells did not develop into follicles,
including the GCs or the oocytes. This result indicates
that transplanted ADSCs did not directly participate in
follicle regeneration. Furthermore, a large number of
engrafted cells died within 1 month after transplantation.
Taken together, these results suggest that the direct regen-
eration of ADSCs played a minor role in the improved
ovary structure and function.
Microarray and real-time PCR analysis
The expression of 326 genes differed between the WT and
the POF groups. One hundred sixty-six and 160 genes in
the POF group were increased and decreased compared
with the WT group, respectively. Compared with the intra-
venous group, 96 genes were upregulated, and 80 genes
were downregulated in the POF group, whereas 150 genesFigure 7 Microarray and real-time PCR analysis. (A) Gene expression in
the intravenous group versus the WT group. (C) Gene expression in the in
Angpt1, Onecut2, and Zcchc11 were upregulated, and Cxcr4 was downreguwere upregulated, and 75 genes were downregulated in the
POF group compared with the in situ group (Figure 7) (ac-
cession number: GSE47741).
The pathways that were changed in the POF group and
the ADSC transportation group compared with the WT
group included genes related to the cytokine-cytokine re-
ceptor interaction, cell-adhesion molecules (CAMs), the
transforming growth factor (TGF)-β signaling pathway, nat-
ural killer cell-mediated cytotoxicity, the MAPK pathway,
and the Toll-like receptor signaling pathway. Some of those
pathways are important for follicle and oocyte growth.
Some genes exhibited different expression levels between
the ADSC therapy group and the POF group. Zcchc11,
Angpt 1, Onecut2, among others, were upregulated after
ADSC therapy in both therapy groups, whereas Cxcr4 was
downregulated, these results are in accordance with our
microarray analysis. However, certain functions of these
genes remain obscure (Figure 7).
ADSCs are known to secrete a number of cytokines, in-
cluding high levels of angiogenic growth factors, such as
HGF (hepatocyte growth factor), VEGF (vascular endothe-
lial growth factor), PGF (placental growth factor), and
TGF-β. ADSCs also exhibit moderate expression of FGF
(fibroblast growth factor)-2 and Ang (angiopoietin)-1, as
well as low levels of Ang-2 [17-20]. Some genes that regu-
late cytokines secretion changed. Furthermore, ADSCsthe intravenous group versus the WT group. (B) Gene expression in
situ group versus the WT group. (D) Relative expression of genes.
lated; these results were in accordance with the microarray result.
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oocytes or GCs. Thus, the observed effect was likely due to
cytokines produced by ADSCs. ADSCs may improve ovar-
ian function via the action of paracrine cytokines.
Some cases of POF clearly have a genetic basis [21]. We
used microarrays to evaluate genes related to ovarian
function. The highly transcribed genes were related to
functional groups such as stem cell cytokines, chemokine
receptors, and transcription regulation.
The increased expression of Angpt1 after therapy was
in accordance with previous research. The change in
Angpt1 and Angpt2 levels may be associated with fol-
licular growth and angiogenesis during the preovulatory
period [22]. Angpt1 is a cytokine secreted by stem cells.
The secretion of Angpt1 makes ADSCs suitable for re-
generative cell therapy [19].
CXCR4, an α-chemokine receptor specific for stromal-
derived-factor-1 (SDF-1, also referred to as CXCL12),
has potent chemotactic activity for lymphocytes and was
downregulated after therapy. CXCR4/SDF1 may play an
important role in retaining follicles in an inactivated
state. The inactivation of CXCR4 may induce the growth
of a primordial follicle into a mature follicle, and the
CXCR4/SDF1 interaction can inhibit the primordial
transition to a primary follicle in the neonatal mouse
[23]. The downregulation of CXCR4 may promote the
growth of primordial follicles into mature follicles.
The Zcchc11 enzyme is implicated in microRNA
(miRNA) regulation. Zcchc11 is also important for post-
natal survival and growth. Zcchc11 deficiency significantly
decreased IGF-1 mRNA in the liver and insulin-like
growth factor (IGF)-1 protein in the blood during the neo-
natal period [24]. IGF-1, a growth-hormone mediator, can
stimulate GC proliferation, inhibit apoptosis, and promote
follicular antrum formation [25,26]. IGF-1 may play a key
role in sensitizing ovarian GCs to follicle-stimulating hor-
mone (FSH) during terminal follicular growth [27] and
also plays an endocrine and/or paracrine role in ovarian
follicular development.
Apoptosis is likely a relevant mechanism in the genesis
of POF in patients who have undergone chemotherapy
or radiotherapy [28]. After ADSC therapy, the number
of TUNEL-positive cells decreased significantly, and
Zcchc11 expression was upregulated, indicating that
ADSCs can reduce POF-mediated apoptosis.
ADSC therapy may be used in clinical applications for
patients who have no distant metastasis. In this scenario,
we can collect the patient’s stem cells and then reinfuse
them after completing chemotherapy. For aggressive
tumors, stem cells can be acquired after chemotherapy,
although cell viability may decline, and the risk of cancer
cell reintroduction may increase. More research is
needed to evaluate the efficacy and safety of ADSC ac-
quired after chemotherapy.In regard to genetic defects, autologous ADSCs will
presumably also carry the same genetic defect. Thus,
ADSCs represent desirable target cells for gene therapy,
as they are susceptible to transfection with exogenous
genes. Experiments have confirmed that ADSCs can eas-
ily import exogenous genes in vitro, and these genes can
be expressed efficiently and for long periods in vivo.
Kucerova [29] used ADSCs as a drug cell carrier to suc-
cessfully inhibit murine melanoma growth. Therefore,
ADSCs are an important tool for the future of gene
therapy.
Conclusions
Our studies revealed that ADSCs significantly improved
ovarian function after chemotherapy-induced ovarian in-
jury. Our results suggest a potential mechanism for
ADSC therapy. ADSCs could increase follicle number
and oocyte number through gene-expression changes
and the production of paracrine cytokines. ADSC treat-
ment also decreased granulosa cells apoptosis. There-
fore, ADSCs represent an alternative strategy for POF
therapy and may be useful for future regenerative medi-
cine and clinical applications.
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